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Abstract 
The prevention of stroke and other thromboembolic events plays a crucial role in the 
management of atrial fibrillation (AF) patients. Not all AF patients are equal in terms of 
thromboembolic risk, therefore not all will benefit from oral anticoagulation treatment. The 
general principle is that the expected benefit of anticoagulation in reduction of 
thromboembolic risk must exceed the expected harm caused by possible bleeding. Some 
guidelines have focused on a categorical approach to stroke prevention, with a focus on 
identifying high risk patients for oral anticoagulation (OAC). Various current guidelines 
recommend assessment of stroke risk using the CHADS2 or CHA2DS2-VASc scores in order 
to initially detect low-risk patients, who require no antithrombotic therapy. However, the 
scores do not incorporate all possible risk factors causing a high thromboembolic risk. Factors 
such as impaired renal function, obstructive sleep apnea, echocardiographic and biochemical 
or coagulation parameters can also predict adverse thromboembolic events. The present 
review aims to describe biomarkers whether blood, urine, imaging (cardiac or cerebral) or 
clinical that go beyond the CHA2DS2-VASc score and potentially aid stroke risk assessment. 
Whilst useful in some cases, the presented parameters should be perhaps used to further refine 
initial identification of low risk patients, following which effective stroke prevention can be 
offered to those with ≥1 additional stroke risk factors. 
 
Key words: atrial fibrillation; CHA2DS2-VASc; CHADS2; thromboembolic risk; stroke 
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Introduction 
Atrial fibrillation (AF) is an independent risk factor for stroke, but not all AF patients have 
equal stroke risk and therefore, not all should be considered in the same manner. Age, sex and 
comorbidities influence thromboembolic risk, and it would be simplistic to regard that all risk 
factors carry equal weight. Various stroke risk factors had led to a development of several risk 
stratification scores, to aid clinical decision-making. The general principle is that the expected 
benefit in reduction of ischemic stroke risk associated with anticoagulation must exceed the 
expected bleeding-related harm. Many of the current guidelines of many scientific societies 
enforce making the decision on whether to use anticoagulation therapy on 1 of the 2 most 
widely used risk-stratification schemes, that is, the CHADS2 or CHA2DS2-VASc scores. 
However, these scores were designed to be simple and practical, and thus, include the 
common stroke risk factors seen in everyday clinical practice. These scores do not include 
many of the less common stroke risk factors, imaging or biomarkers, and in this review 
article, we aim to look beyond the common stroke risk factors within these 2 clinical risk 
scores. 
 
CHADS2 and CHA2DS2-VASc scores: where are we now? 
Over the last few decades several epidemiological studies aimed to describe factors 
influencing the stroke risk in AF patients. The CHADS2 score was developed from the risk 
factors for stroke seen in the non-warfarin arms of the historical trials cohorts, amalgamating 
the risk stratification schemes of the AF Investigators and the SPAF Investigators [1]. The 
CHADS2 score was validated in the hospitalised cohort of the National Registry of Atrial 
Fibrillation (NRAF) study. Using the CHADS2 score, points are assigned for history of 
(recent decompensated) Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes 
mellitus and history of Stroke or transient ischemic attach. The CHADS2 score was simple, 
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and promptly found its place in clinical practice. Over the years following its introduction, the 
limitations of the CHADS2 score were increasingly evident [2, 3]. Indeed, external validations 
of the score and reviews that compared CHADS2 with other risk assessment schemes 
confirmed the poor ability of the CHADS2 score in distinguishing ‘high risk’ patients who 
will benefit from anticoagulation [2, 4]. Also, the CHADS2 score poorly identified low-risk 
patients [5], resulting in high rates of thromboembolic events even in presumably low-risk 
patients.  
In 2010, the CHA2DS2-VASc was proposed, which incorporated factors omitted in the 
original CHADS2 score but included additional ‘non-CHADS2 risk factors’, namely age 65-
74, vascular disease (myocardial infarction, peripheral artery disease, complex aortic plaque) 
and female sex [6] [Table 1]. Many subsequent analyses showed that the CHA2DS2-VASc 
particularly helped distinguish patients who were at low-risk where antithrombotic therapy 
was not indicated
. 
Table 2 summarises the annual stroke and thromboembolism risk according 
to the CHADS2 and CHA2DS2-VASc scores [7].  
Given that risk scores solely based on clinical risk factors only have modest predictive 
value for high risk patients, and that prior guideline strategies focused on a categorical (that 
is, low, moderate and high) risk strata approach to stroke prevention led to under-treatment of 
the high risk patients, a different focus was clearly needed. In addition, stroke risk is a 
continuum, and the artificial categorization of stroke risk into low, moderate and high risk 
strata simply had not improved optimal thromboprophylaxis amongst AF patients, especially 
amongst the ‘high risk’ category [5]. 
The approach associated with the introduction of CHA2DS2-VASc score changed 
clinical practice. In the 2012 focused update of the European Society of Cardiology 
guidelines, there was a recommendation that instead of focusing on the identification of high 
risk patients, a clinical practice shift was recommendation so that the initial step was the 
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identification of ‘truly low risk’ patients (that is, CHA2DS2-VASc score 0 in males, 1 in 
females) who did not need any antithrombotic therapy. The subsequent step was to offer 
effective stroke prevention (i.e. oral anticoagulation) to patients with 1 or more additional 
stroke risk factors. Indeed, Olesen et al. found that a CHADS2 = 0 was not ‘low risk’ and that 
the annual stroke risk in this group may be as high as 3.2% [8]. 
Guidelines do differ in their approaches. In the European Society of Cardiology and 
American Heart Association/American College of Cardiology/Heart Rhythm Society 
(AHA/ACC/HRS), the use of CHA2DS2-VASc score is recommended [9, 10]. However, in 
the European Society of Cardiology guidelines only patients with CHA2DS2-VASc score = 0 
in males (or 1 in females) are not recommended oral anticoagulation, while all the others with 
≥1 stroke risk factors a recommended (or should consider) oral anticoagulants. The 2014 
AHA/ACC/HRS agree with no anticoagulation in patients with CHA2DS2-VASc score = 0, 
but in those with a CHA2DS2-VASc score = 1 the recommendation is ‘nothing, aspirin or oral 
anticoagulation’.  
The guidelines of the Canadian Cardiovascular Society and the American College of 
Chest Physicians also opt for using the CHADS2 score [11, 12]. Again, they also agree on no 
coagulation in CHADS2 = 0 patients, but the Canadian Cardiovascular Society assigns oral 
anticoagulation to all patients with a score ≥1 or those age ≥65 years, with aspirin 
recommended in AF patients age <65 years with vascular disease. The 2012 American 
College of Chest Physicians guidelines are based on the CHADS2 score, but in those with a 
CHADS2 score = 0, they recommend consideration of ‘non CHADS2’ risk factors (i.e. age 65-
74, vascular disease and female gender) where oral anticoagulation may be considered. 
Details regarding the differences in all 4 guidelines are described in Figure 1 [13]. 
 
Beyond the CHA2DS2-VASc score 
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As discussed above, the CHA2DS2-VASc score includes the common stroke risk 
factors seen in everyday clinical practice. Apart from left ventricular impairment or complex 
aortic plaque on echocardiography, the CHA2DS2-VASc score does not include any imaging 
or biomarker parameters, nor some of the less common clinical stroke risk factors. 
 
Impaired renal function 
Chronic kidney disease is common in AF patients, and between 10 and 15% of all AF 
patients meet the criteria for the diagnosis [9]. The prevalence of AF also rises with the 
severity of renal function impairment. For example, amongst AF patients with estimated 
glomerular filtration rate <45 ml/min, the prevalence of AF was approximately 20% [14]. 
Common risk factors are responsible for development of both AF and chronic kidney disease 
– indeed, these include hypertension, diabetes mellitus, impaired endothelial function and 
inflammation, and all are associated with elevated thromboembolic risk. 
Impaired renal function impairment is associated with increased thromboembolic risk 
in AF. For example, in female patients with AF, a history of stroke or transient ischemic 
attack has been linked with 7-fold increase in the stroke risk, whilst renal dysfunction resulted 
in an 11-fold increase [15]. 
One analysis of AF patients categorized according the risk assessed in the CHADS2 
score found that in the control group (patients with normal renal function) approximately 70% 
of patients were classified as CHADS2 0 or 1 points, while in the group with CKD stage >III 
almost 70% had CHADS2 ≥2 points [16]. This accentuated risk with chronic kidney disease in 
AF patients led to a proposal to include chronic kidney disease into the existing CHA2DS2-
VASc scheme, whereby the little “c” on the end of the acronym was proposed to be translated 
as “chronic severe renal impairment” [17].  
In the interim, the R2CHADS2 score was proposed based on an analysis of the 
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ROCKET AF study [18]. The initial “R2” in the acronym stood for renal dysfunction and 
meant that a patients was assigned 2 additional point when his glomerular filtration rate was 
<60 mL/min. The initial analysis showed that the predictive value of this score was 
comparable to CHADS2 and CHA2DS2-VASc, but has several major limitations. Also, the 
derivation of R2CHADS2 was from a selected anticoagulated clinical trial cohort, which only 
included high risk subjects (CHADS2 score ≥2, and those with score=2 were capped at 10%) 
and those with creatinine clearance <30 mL/min were excluded.  
Various ‘real world’ cohorts with a broad spectrum of stroke risk and renal function 
showed that renal function did not significantly improve the prediction value of the 
CHA2DS2-VASc score for identifying high risk patients. For example, Roldán et al. showed 
that adding chronic kidney disease to CHADS2 nor CHA2DS2-VASc in AF patients did not 
provide additional benefit in risk stratification [19]. Renal impairment is associated with heart 
failure, age, diabetes, vascular disease, etc. – which are components within the CHA2DS2-
VASc score. Thus, it would be difficult to show an incremental predictive advantage in stroke 
prediction by adding renal impairment to CHA2DS2-VASc. 
There is little doubt that chronic kidney disease in AF patients represents a high risk 
group. For example, Lin et al. identified 338 individuals with CHA2DS2-VASc score of 0–1 
points and followed them for systemic thromboembolic events, including acute ischemic 
stroke, transient ischemic attack, and peripheral artery embolism [20]. In low-risk patients 
without the chronic kidney disease annual event rate was 0.2%, whereas with chronic kidney 
disease patients the event rate was 2.9% (p<0.001). Similar conclusions were evident in a 
study of patients after AF ablation [21], where in patients with CHA2DS2-VASc score of 0–1 
presence of chronic kidney disease was associated with a 14-fold increase in the rate of 
thromboembolic events. Therefore all AF patients with chronic kidney disease are at 
increased risk of thromboembolic events. 
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Obstructive sleep apnea 
Obstructive sleep apnea is among the more novel cardiovascular risk factors, 
associated with a number of cardiovascular diseases, including hypertension, coronary artery 
disease, myocardial infarction, stroke or arrhythmias. This translates into elevated risk of 
stroke seen in but this seems to be related to several factors, including a prothrombotic state, 
but endothelial dysfunction, intermittent hypoxia, variations in intrathoracic pressure, and 
recurrent arousals associated with increased heart rate and blood pressure [22]. 
The prevalence of obstructive sleep apnea amongst AF patients is very high. In the 
general population, the estimated obstructive sleep apnea prevalence is 2-4%, while in AF 
patients referred for ablation, obstructive sleep apnea was found in nearly 46% of cases [23]. 
Recently, obstructive sleep apnea and AF, along with erectile dysfunction, have been 
proposed to be a single clinical entity. [24] 
Obstructive sleep apnea is directly and independently associated with elevated 
thromboembolic risk in AF. Our study included 254 AF patients who underwent polygraphy 
for a diagnosis of OSA and had their thromboembolic risk assessed using the CHADS2 and 
CHA2DS2-VASc scores [25]. The patients with obstructive sleep apnea had significantly 
higher CHADS2 and CHA2DS2-VASc scores, and with along with the increasing obstructive 
sleep apnea severity – expressed by higher values of the apnea-hypopnea index, also the mean 
risk score rose. A paper by Yaranov et al. [26] found that in patients with CHA2DS2-VASc = 
0, the presence of obstructive sleep apnea increased the risk of stroke by 62%.  
 
Other clinical risk factors associated with increased thromboembolism 
Amyloid is a fibrous protein aggregate composed of various form of inappropriately 
folded proteins and polypeptides. It is associated with degenerative diseases of central 
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nervous system and the heart. One of its sub-forms - serum amyloid protein A is considered to 
be an inflammatory cytokine. Elevated serum amyloid protein A levels have been found in 
AF patients and are associated with atrial remodelling and inflammatory state and promotes 
vascular thrombosis. This association is confirmed by higher levels of serum amyloid protein 
A found in patients with venous thromboembolism compared to control group. A different 
type of the protein, namely β-amyloid is extensively deposited within the walls of small 
vessels, especially in the elderly. The presence of amyloid angiopathy in the cerebral vessels 
predisposes to higher risk for thromboembolic events but also for intracranial hemorrhage 
related to anticoagulation [27].  
Also, some myocardial disease like obstructive hypertrophic cardiomyopathy (HC) are 
linked with alterations in coagulation parameters. In obstructive HC patients various 
indicators of the coagulation activation are found. They include elevated levels of plasma 
fibrinopeptide A and thrombin-antithrombin HI complex. Nearly 15% of HC patients develop 
AF, and such patients are at high risk of stroke and thromboembolism [28]. Others have 
proposed the addition of hyperlipidaemia and smoking to CHA2DS2–VASc, the so-called 
CHA2DS2-VASc-HS score, proposed in order to predict vascular events, not 
thromboembolism [29]. 
 
Echocardiography  
Echocardiography is among the most often used imaging techniques used in AF 
patients. Transesophageal echocardiography is a method more accurate in assessing left atrial 
appendage size, function and presence of thrombus. It is routinely used prior to cardioversion 
or catheter ablation to prevent procedure–related thromboembolism. Nevertheless, the 
transthoracic echocardiography also plays a role in the thromboembolic risk stratification of 
AF patients. Transthoracic echocardiography is a method more accessible and more often 
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used. Recent guidelines of the National Institute for Health and Clinical Excellence (NICE) 
state that transesophageal echocardiography may help in assessment of patients, in whom 
refinement of clinical risk stratification for antithrombotic therapy is needed. [30] 
Utility of both imaging techniques in the stroke assessment has been proven in 
numerous studies, which are briefly summarized in the Table 3 (modified from Providência et 
al. [31]). Most of the prognostic factors described in the literature are associated to the left 
atrium morphology and function.  
As we have recently shown, the simplest measurement derived from left atrial 
diameter is a good predictor of thromboembolic risk [40], whereby atrial enlargement is not 
only related to the higher risk scores, but similarly as in the case of obstructive sleep apnea, 
the thromboembolic risk rises along with the rising left atrial size. 
There is a relation between CHADS2 and CHA2DS2-VASc scores and left atrial 
remodelling status including its maximum volume index, total emptying fraction and mean 
strain [31]. Other described echocardiographic parameters include mechanical discordance, 
electromechanical delay or increased orifice size and decreased flow velocity of left atrial 
appendage, spontaneous contrast, smoke, sludge, or thrombus [41]. 
 
Biomarkers 
There have been a wide plethora of biomarkers that have been tested in AF, and have 
been related to prognosis and stroke risk in AF. These biomarkers include those related to 
myocardial stress or injury (i.e. troponins, natriuretic peptides), altered coagulation (D-dimer, 
plasminogen activator inhibitor, tissue factor, P-selectin), endothelial damage/dysfunction 
(thrombomodulin, E-selectin, von Wilebrand factor), inflammation (C-reactive protein, 
interleukin-6, tumour necrosis factor-α), fibrosis and extracellular matrix turnover 
(transforming growth factor-β, myeloperoxidase, metallopeptidases and their inhibitor) or 
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genetic factors (micro RNA, single-nucleotide polymorphisms) [42].  
Stroke and thromboembolic events in AF patients are caused mainly by alteration in 
the 3 components of Virchow’s triad, as follows: (i) abnormal blood flow (blood stasis in the 
left atrium), (ii) vessel wall abnormalities (endothelial and endocardial damage/dysfunction, 
oxidative stress) and (iii) abnormal blood constituents.  
Table 4 (modified from Kornej et al. [42]) shows a wide spectrum of the biomarkers 
that have been associated with stroke or adverse thromboembolic events in patients with AF 
[Table 4]. Of course, a balance is needed between complex additional biomarker tests that 
require time and generate costs, and practical simplicity of risk prediction schemes used in 
clinical practice in busy wards or clinics. Thus, more emphasis now put on the initial 
identification of “truly low risk” patients, and therefore biomarkers with high negative-
predictive value for ruling out thrombosis may be particularly useful.  
Endothelial damage/dysfunction often measured by levels of circulating von 
Wilebrand factor was the first biomarker shown to help refined clinical risk stratification in 
AF, improving the predictive value of the CHADS2 and Birmingham scores [57]. Other 
factors include uric acid that was also useful in refining risk assessment [58]. The addition of 
troponin to risk assessment scheme similarly helped identify patients with higher risk of 
intracardiac thrombi as seen on the echocardiography [59]. Another marker of myocardial 
stress, that is, N-terminal pro–B-type natriuretic peptide provides complementary prognostic 
information to the CHA2DS2–VASc score [60]. More recently, growth differentiation factor 
15 a novel marker of oxidative stress and inflammation was tested in an anticoagulated 
clinical trial population [61]. Higher growth differentiation factor 15 concentrations were 
associated with a risk stroke or systemic embolism, major bleeding and death, and the 
association in this selected trial cohort remained significant after adjustment for risk factors 
included in the CHA2DS2-VASc score.  
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Adding large number of biomarkers (listed in table 5.) may help improve prediction of 
‘high risk’ but would be at the cost or disadvantage of adding substantial complexity, expense 
and lack of practicality especially where rapid decisions are needed. [Table 5] Extensive and 
complex biochemical, imaging, and physical assessment are perhaps not mandatory in every 
AF patient to decide on anticoagulation. Whilst useful in some cases, the presented 
parameters should be perhaps used to further refine the initial identification of low risk 
patients, following which effective stroke prevention can be offered to those with ≥1 
additional stroke risk factors. Proposed scheme for the AF patients screening for additional 
non-CHA2DS2-VASc risk factors is proposed in the figure 2. [Figure 2] 
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Figure legends. 
Figure 1. Comparison of risk assessment schemes used in different guidelines [21]. 
Figure 2. Proposed flow-chart for thromboembolic risk assessment in atrial fibrillation 
patients. 
 ACCP – American College of Chest Physicians, AHA/AC/HRS – American 
Heart Association/American College of Cardiology/Heart Rhythm Society, 
CCS – Canadian Cardiovascular Society, CKD – chronic kidney disease, CrCl 
– creatinine clearance, ESC - European Society of Cardiology, vit. K – vitamin 
K. 
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Table 1. Comparison of the CHADS2 and CHA2DS2-VASc scores.  
LVEF – left ventricular ejection fraction 
  *criteria from the validation study 
CHADS2  CHA2DS2-VASc 
Description* Points Letter Points Description* 
Recent heart failure 
exacerbation 
1 C 1 
Moderate to severe systolic 
left ventricular 
dysfunction, LVEF ≤40%, 
or recent decompensated 
heart failure requiring 
hospitalization 
History of hypertension 1 H 1 History of hypertension 
Age ≥75 years 1 A 2 Age ≥75 years 
Diabetes mellitus 1 D 1 Diabetes mellitus 
History of stroke or 
transient ischemic attack 2 S 2 
History of stroke, transient 
ischemic attack or 
thromboembolism 
  
V 1 
History of myocardial 
infarction, complex aortic 
plaque or peripheral artery 
disease 
  A 1 Age 65 to 74 years 
  Sc 1 Female sex 
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Table 2. Comparison of the annual hospital admission and death rates due to 
thromboembolism (includes peripheral artery embolism, ischaemic stroke, and 
pulmonary embolism) as assessed by CHADS2 and CHA2DS2-VASc scores. 
 
CHADS2  CHA2DS2-VASc 
Annual risk Points Annual risk 
1.7% (1.5-1.9) 0 0.8% (0.6-1.0) 
4.8% (4.5-5.1) 1 2.0% (1.7-2.4) 
7.3% (6.9-7.8) 2 3.7% (3.4-4.1) 
15.5% (14.6-16.4) 3 5.9% (5.5-6.3) 
21.6% (20.0-23.2) 4 9.3% (8.7-9.9) 
19.7% (16.9-23.0) 5 15.3% (14.4-16.2) 
22.4% (14.6-34.3) 6 19.7% (18.2-21.4) 
 7 21.5% (18.8-24.6) 
 8 22.3% (16.3-30.8) 
 9 23.6% (10.6-52.6) 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Table 3. Echocardiography parameters in prediction of various thromboembolic events in atrial fibrillation patients. 
Study  Year Number of 
participants, type 
of AF 
Parameter 
 
Main findings 
TRANSTHORACIC ECHOCARDIOGRAPHY 
SPAF 
Investigators 
[32] 
1992 568 + non-
rheumatic 
14 transthoracic variables i.e. LA size, LV 
posteriori wall, LV end diastolic/systolic 
dimensions, regional dysfunction 
LA size and depressed LVEF were independent 
predictors of thromboembolism 
Osranek et al. 
[33] 
2005 46 + lone LA volume index, LV ejection fraction LA volume ≥32 mL/m2 was associated worse 
event-free survival 
Lee et al. [34] 2008 330 + persistent E/E’ ratio E/E’ ratio was independently associated with 
ischemic stroke 
Shin et al. [35] 2010 148 + AF and heart 
failure with 
preserved EF 
S’ and E’ S’ and E’, were predictors of a composite of 
cardiovascular death, recurrent heart failure, and 
ischemic stroke 
Azemi et al. 
[36] 
2012 57 + non-valvular LA strain 
 
 
 
Reduced peak negative and peak positive LA strain 
values in patients with stroke 
 
TRANSESOPHAGEAL ECHOCARDIOGRAPHY 
Zabalgoitia et 
al. [37] 
1998 789 + non-valvular LA appendage thrombi, dense SEC, LA 
appendage peak flow velocities ≤20 
cm/sec, complex aortic plaque 
All factors were associated with increased 
thromboembolic risk 
SPAF 
Committee on 
Echocardiograp
hy [38] 
1998 382 + non-valvular LA abnormality, complex aortic plaque, 
LA appendage abnormality 
LA abnormality, complex aortic plaque, LA 
appendage abnormality was associated with high 
risk for stroke 
Dawn et al. 
[39] 
2005 175 
 
LA appendage thrombus, LA SEC LA appendage thrombus and LA SEC were 
predictors of cardiovascular death 
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AF, atrial fibrillation; LA, left atrium; LV, left ventricle; LVEF, left ventricular ejection fraction; SEC, spontaneous echocardiographic contrast; 
SPAF III, Stroke Prevention in Atrial Fibrillation III; 
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Table 4. Biomarkers in prediction of various thromboembolic events in atrial fibrillation patients 
 
Study Year Participants Biomarker Investigation 
Heppell et al. 
[43] 
1997 109 BTG, von Wilebrand factor Association with presence of left atrial thrombosis 
Mondillo et al. 
[44] 
2000 45 chronic 
AF, 35 
control 
von Wilebrand factor, 
thrombomodulin 
Higher levels in chronic AF; association with a prothrombotic state 
and endothelial dysfunction, coagulation factors and left atrial 
dimension 
Conway et al. 
[45] 
2003 994 AF 
patients 
taking aspirin 
von Wilebrand factor, P-
selectin 
Rise in von Wilebrand was predictive of stroke and vascular events 
Conway et al. 
[46] 
2004 106 AF; 41 
control 
Interleukin 6, CRP, TF Higher levels in AF patients; TF associated with stroke risk 
Heeringa et al. 
[47] 
2006 162 AF, 324 
control 
P-selectin Association with adverse outcomes in AF 
Nozawa et al. 
[48] 
2006 509 D-dimer Prediction of thromboembolic events even in AF patients on 
anticoagulation 
Ferro et al. 
[49] 
2007 285 CD-40 ligand Predictor of vascular events (stroke and myocardial infarct) 
Lip et al. [50] 2007 880 hsCRP Correlation with stroke risk factors and prognosis (mortality, 
cardiovascular events) 
Kurl et al. [51] 2009 958 NT-proBNP, NT-proANP Predictor for stroke and AF in men 
Pinto et al. 
[52] 
2009 373 TNF-a, IL-6, von Wilebrand 
factor 
Predictor for new-onset stroke in persistent AF 
Yuce et al. 
[53] 
2010 205 chronic 
AF 
MPV MPV is not related with left atrial thrombus in patients with chronic 
AF 
Sadanaga et 
al. [54] 
2011 261 BNP Association with thromboembolic events in patients with AF during 
oral anticoagulant therapy 
Hijazi et al. 
[55] 
2012 6 189 NT-proBNP, Troponin I Association with risk for stroke and mortality 
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AF, atrial fibrillation; BTG, β-thromboglobulin; CHF, chronic heart failure; CRP, C-reactive protein; HF, heart failure; hsCRP, highly sensitive 
C-reactive protein; IL, interleukin; LAA, left atrial appendage; MMP, metallopeptidase; MPV, mean platelet volume; NT-proANP, N-terminal 
prohormone of ANP; NT-proBNP, N-terminal prohormone of BNP; OAC, oral anticoagulants; SPAF III, Stroke Prevention in Atrial Fibrillation 
III; TF, tissue factor; TNF, tumour necrosis factor;  
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Table 5.  Some of the factors associated with an increased thromboembolic risk, that are 
not issued in the CHA2DS2-VASc score. 
NT-proBNP, N-terminal pro-B-type natriuretic protein 
Factors associated with an increased thromboembolic risk, that are not 
issued in the CHA2DS2-VASc score 
- chronic kidney disease 
- obstructive sleep apnea 
- left atrial enlargement 
- left atrial strain 
- atrial mechanical discordance, electromechanical delay or increased 
orifice size 
- decreased flow velocity of left atrial appendage 
- echocardiographic spontaneous contrast, smoke, sludge, or thrombus 
- troponin 
- NT-proBNP 
- adiponectine 
- D-dimer 
- smoking 
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ESC
2012 
AHA/ACC/HRS
2014
ACCP
2012
CCS
2014 
CHA2DS2-VASc CHA2DS2-VASc CHADS2 CHADS2
CHA2DS2-VASc = 0
no antithrombotic
treatment
CHA2DS2-VASc = 0
no antithrombotic
treatment
CHADS2 = 0
no antithrombotic
treatment
CHADS2 = 0
no antithrombotic
treatment if no 
vascular disease
CHA2DS2-VASc
≥ 1
CHA2DS2-VASc
= 1
CHADS2
= 1
Aspirin
recommended if
vascular disease
and age < 65 years
Oral
anticoagulant
therapy (prefered
non-vitamin-K)
no antithrombotic
therapy, or
treatment with an
oral anticoagulant
or aspirin may be 
considered
Oral anticoagulant
therapy preferred; 
antiplatelet therapy
recommended only for 
patients deemed
unsuitable for or
choose not to take an
oral anticoagulant
CHADS2
≥ 1
Antiplatelets
recommended
only for those
who refuse
oral anticoagulant
therapy]
CHA2DS2-VASc
≥ 2
CHADS2
≥ 2
Oral
anticoagulant
therapy
recommended
Non-vit K 
antagonists prefered
over vit. K atagonists
(dabigatran 150 mg 
twice daily preferred)
Vit. K antagonists
in patients
with end-stage
CKD (CrCl <15 
mL/min) or
hemodialysis
Aspirin and 
clopidogrel
recommended when
deemed unsuitable
for or who choose
not to take an oral
anticoagulant
Oral
anticoagulant
therapy (prefered
non-vitamin-K)
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Patient with non-valvular AF 
Assess thromboembolic risk risk using the CHA2DS2-VASc score 
CHA2DS2-VASc ≥ 1 in men 
or 
CHA2DS2-VASc ≥ 2 in women 
Anticoagulation treatment, 
preferably NOAC 
YES 
NO 
Perform additional risk assessment: 
• for OSA (medical history, physical 
examination, Epworth sleepiness 
scale or polysomnography) 
• for renal function impairment 
(creatinine, glomelular filtration rate) 
• for LA thrombus, other ECHO 
indices of thromboembolic risk (TTE 
and/or if applicable TEE) 
• for biochemical thromboembolism 
biomarkers (uric acid, lipids, D-dimer, 
BNP, NT-proBNP, vWF, and others, 
where available ) 
• for other risk factors feasible in real-
life risk stratification (i.e. dyslipidemia, 
smoking etc.) 
Many / one strong additional 
thromboembolic risk factor 
NO 
Consider 
anticoagulation treatment, 
preferably NOAC 
Do not use anticoagulation 
treatment 
YES 
